Enhancing Prostate Cancer Classification: A Comprehensive Review of Multiparametric Mri and Deep Learning Integration Publisher



G Valizadeh GELAREH ; M Morafegh MAHMOUD ; F Fatemi FATEMEH ; M Ghafoori MAHYAR ; H Saligheh Rad HAMIDREZA
Source: Journal of Magnetic Resonance Imaging Published:2025

Abstract

Multiparametric MRI (mpMRI) has become an essential tool in the detection of prostate cancer (PCa) and can help many men avoid unnecessary biopsies. However, interpreting prostate mpMRI remains subjective, labor-intensive, and more complex compared to traditional transrectal ultrasound. These challenges will likely grow as MRI is increasingly adopted for PCa screening and diagnosis. This development has sparked interest in non-invasive artificial intelligence (AI) support, as larger and better-labeled datasets now enable deep-learning (DL) models to address important tasks in the prostate MRI workflow. Specifically, DL classification networks can be trained to differentiate between benign tissue and PCa, identify non-clinically significant disease versus clinically significant disease, and predict high-grade cancer at both the lesion and patient levels. This review focuses on the integration of DL classification networks with mpMRI for PCa assessment, examining key network architectures and strategies, the impact of different MRI sequence inputs on model performance, and the added value of incorporating domain knowledge and clinical information into MRI-based DL classifiers. It also highlights reported comparisons between DL models and the Prostate Imaging Reporting and Data System (PI-RADS) for PCa diagnosis and the potential of AI-assisted predictions, alongside ongoing efforts to improve model explainability and interpretability to support clinical trust and adoption. It further discusses the potential role of DL-based computer-aided diagnosis systems in improving the prostate MRI reporting workflow while addressing current limitations and future outlooks to facilitate better clinical integration of these systems. Evidence Level: N/A. Technical Efficacy: Stage 2. © 2025 Elsevier B.V., All rights reserved.